Market Overview

Sanofi Shares Rise After Company Agrees To Sell Nichi-Iko Pharma Stake

Share:

Shares of Sanofi SA (ADR) (NYSE: SNY) were trading higher by nearly 5 percent on Monday after the company agreed to sell its stake in Japan-based Nichi-Iko Pharma.

According to France-based Boursier.com, Sanofi will sell its 4.76 percent stake in Nichi-Iko Pharma which is valued at approximately 55.7 millions euros. The publication added that the sale will take place prior to Tuesday's market session.

Investors were also encouraged by an announcement that Sanofi and its vaccines global business unit Sanofi Paste announced the first public dengue immunization program has started in the Philippines. The program will result in the vaccination of 1 million students across 6,000 public schools this year in three highly dengue-endemic regions of the country.

Olivier Charmeil, Executive Vice President, Sanofi Pasteur, commends the Philippines on the launch of the first public dengue immunization program in the world: "The Philippines' scientific and healthcare communities have been important collaborators in the development of Dengvaxia®, participating in all three phases of the clinical study program that involved over 40,000 individuals from 15 countries. Ensuring access to this approved vaccine in a public immunization program attests to the Filipino health authority's commitment to add this new dengue prevention tool to their integrated disease management strategy for a disease that continues to represent a major public health threat to their country."

Posted-In: France France Companies Nichi-Iko Pharma Olivier Charmeil Sanofi Sanofi PasteurNews Asset Sales

 

Related Articles (SNY)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Credit Suisse Gets 'Back In The Saddle' With Schlumberger, Sets Outperform Rating

Do More Jobs = Quicker Interest-Rate Hike?